Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Ardelyx Inc (Ardelyx) is a biopharmaceutical company that discovers, develops and commercializes first-in-class medicines that advance patient care. The company offers products such as IBSRELA (tenapanor) tablets and XPHOZAH (tenapanor) tablets for the treatment of irritable bowel syndrome with constipation (IBS - C) and chronic kidney disease (CKD) with hyperphosphatemia. It also develops RDX10531 a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. The company offers digital-first, high-touch patient services program that access medical office workflows and connecting patients with their healthcare providers. Ardelyx is headquartered in Waltham, Massachusetts, the US.
Headquarters
United States of America
Address
Suite 210, 400 Fifth Avenue, Waltham, Massachusetts, 02451
Website
www.ardelyx.com
Telephone
1 617 6752739
No of Employees
489
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ARDX (NASD)
Revenue (2024)
$407.3M
22.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-57.4%
(2024 vs 2023)
Market Cap*
$847.2M
Net Profit Margin (2024)
XYZ
-28.9%
(2024 vs 2023)
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| Xphozah (tenapanor) Tablets | XPHOZAH |
| Ibsrela (tenapanor) Tablets | ArdelyxAssist |
| IBSRELA |
Competitor Comparison
| Key Parameters | Ardelyx Inc | Ironwood Pharmaceuticals Inc | Akebia Therapeutics Inc | Shanghai Alebund Pharmaceuticals Ltd | Synergy Pharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | China | United States of America |
| City | Waltham | Boston | Cambridge | Shanghai | New York City |
| State/Province | Massachusetts | Massachusetts | Massachusetts | Shanghai | New York |
| No. of Employees | 489 | 100 | 194 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Raab | President; Chief Executive Officer; Director | Executive Board | 2009 | 61 |
| Sue Hohenleitner | Chief Financial Officer | Senior Management | 2025 | - |
| Felecia W. Ettenberg | Chief Legal Officer | Senior Management | 2026 | - |
| Rajani Dinavahi, M.D. | Chief Medical Officer | Senior Management | 2026 | - |
| David Rosenbaum | Head - Drug Discovery and Early Development | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer